Biological Therapy Plus Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2007-10-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies such as rituximab can locate cancer cells and either kill
them or deliver cancer-killing substances to them without harming normal cells. Biological
therapies such as CpG 7909 use different ways to stimulate the immune system and stop cancer
cells from growing. Combining CpG 7909 with rituximab may kill more cancer cells.
PURPOSE: Phase I trial to study the effectiveness of CpG 7909 plus rituximab in treating
patients who have relapsed or refractory non-Hodgkin's lymphoma.